Immunoglobulin Fab Fragments

• 

  Subject Areas on Research

  • "Rescue" platelet GP IIb/IIIa inhibitor therapy in percutaneous coronary intervention: bailing out of a sunken ship. 
  • 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. 
  • A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results. 
  • A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. 
  • A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study. 
  • A rapid troponin I assay is not optimal for determination of troponin status and prediction of subsequent cardiac events at suspicion of unstable coronary syndromes. 
  • A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes. 
  • Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing. 
  • Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. 
  • Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study. 
  • Abciximab readministration: results of the ReoPro Readministration Registry. 
  • Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. 
  • Activation of human B lymphocytes. XIV. Characterization of the precursor of the pokeweed mitogen-induced anti-sheep red blood cell plaque-forming cell. 
  • Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy. 
  • Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators. 
  • Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. 
  • Acute profound thrombocytopenia after c7E3 Fab therapy. 
  • Adverse Events in the Efficacy of Crotalidae Polyvalent Immune Fab Antivenom vs Placebo in Recovery from Copperhead Snakebite Trial. 
  • An Enrichment Strategy For Sepsis Clinical Trials. 
  • An overview of the results of the EPIC trial. 
  • Anti-epidermal-cell-surface pemphigus antibody detaches viable epidermal cells from culture plates by activation of proteinase. 
  • Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. 
  • Antibodies against the CD44 p80, lymphocyte homing receptor molecule augment human peripheral blood T cell activation. 
  • Antibodies as specific renin inhibitors: studies with polyclonal and monoclonal antibodies and Fab fragments. 
  • Antibody binding to a conformation-dependent epitope induces L-selectin association with the detergent-resistant cytoskeleton. 
  • Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. 
  • Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
  • Antithrombotic therapy in patients undergoing coronary angioplasty. 
  • Are international differences in the outcomes of acute coronary syndromes apparent or real? A multilevel analysis. 
  • Assessing the value of newer pharmacologic agents in non-ST elevation patients: a decision support system application. 
  • Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. 
  • Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS. 
  • Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. 
  • Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS. 
  • Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure. 
  • Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. 
  • CD44 antibody against In(Lu)-related p80, lymphocyte-homing receptor molecule inhibits the binding of human erythrocytes to T cells. 
  • Catabolism of radioiodinated murine monoclonal antibody F(ab')2 fragment labeled using N-succinimidyl 3-iodobenzoate and Iodogen methods. 
  • Catastrophic acute ischemic stroke after Crotalidae polyvalent immune Fab (ovine)-treated rattlesnake envenomation. 
  • Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment. 
  • Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. 
  • Certolizumab pegol. 
  • Changes in oligosaccharide chains of autoantibodies to GRP78 expressed during progression of malignant melanoma stimulate melanoma cell growth and survival. 
  • Characteristics and Outcomes of Suspected Digoxin Toxicity and Immune Fab Treatment Over the Past Two Decades-2000-2020. 
  • Characterization of antibodies to canine renal renin. Studies of interspecies homology of renin using antibodies as probe. 
  • Clinical and pharmacokinetic profiles of digoxin immune Fab in four patients with renal impairment. 
  • Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. 
  • Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. 
  • Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials. 
  • Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. 
  • Clinical utility of serial and continuous ST-segment recovery assessment in patients with acute ST-elevation myocardial infarction: assessing the dynamics of epicardial and myocardial reperfusion. 
  • Coagulation parameters in copperhead compared to other Crotalinae envenomation: secondary analysis of the F(ab')2 versus Fab antivenom trial. 
  • Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. 
  • Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial). 
  • Comparative localization of murine monoclonal antibody Me1-14 F(ab')2 fragment and whole IgG2a in human glioma xenografts. 
  • Comparative tissue distribution in mice of the alpha-emitter 211At and 131I as labels of a monoclonal antibody and F(ab')2 fragment. 
  • Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. 
  • Comparison of F(ab')2 versus Fab antivenom for pit viper envenomation: a prospective, blinded, multicenter, randomized clinical trial. 
  • Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). 
  • Comparison of angioplasty with stenting in acute myocardial infarction. 
  • Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. 
  • Comparison of catheterization laboratory initiated abciximab and eptifibatide during percutaneous coronary intervention in acute coronary syndromes (an ACUITY substudy). 
  • Comparison of in vivo efficacy and mechanism of action of antimurine monoclonal antibodies directed against TCR alpha beta (H57-597) and CD3 (145-2C11). 
  • Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. 
  • Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. 
  • Continuous IV Crotalidae Polyvalent Immune Fab (Ovine) (FabAV) for selected North American rattlesnake bite patients. 
  • Control of venom-induced tissue injury in copperhead snakebite patients: a post hoc sub-group analysis of a clinical trial comparing F(ab')2 to Fab antivenom. 
  • Copperhead snakebite treated with crotalidae polyvalent immune fab (ovine) antivenom in third trimester pregnancy. 
  • Cost effectiveness of abciximab during routine medical practice. 
  • Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial. 
  • Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis. 
  • Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. 
  • Crotalidae polyvalent immune Fab (ovine) antivenom is efficacious for envenomations by Southern Pacific rattlesnakes (Crotalus helleri). 
  • Crotaline Fab antivenom for the treatment of children with rattlesnake envenomation. 
  • Crotaline Fab antivenom for treatment of children with rattlesnake envenomation. 
  • Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region. 
  • Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease. 
  • Current status of cardiac surgery in the abciximab-treated patient. 
  • Cytochrome oxidase: structural insights from electron microscopy and from secondary structure prediction. 
  • Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. 
  • Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment. 
  • Difficulties in applying clinical trial information to the practice setting: case of a high-cost drug. 
  • Digoxin measurements following plasma ultrafiltration in two patients with digoxin toxicity treated with specific Fab fragments. 
  • Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data. 
  • Dosing and administration of ReoPro (c7E3 Fab). 
  • ESPRIT in context: pharmacology matters! 
  • Early activation and cell cycle entry of resting B cells after Fab-anti-Ig treatment: role of receptor crosslinking. 
  • Early administration of Fab antivenom resulted in faster limb recovery in copperhead snake envenomation patients. 
  • Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction. 
  • Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. 
  • Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. 
  • Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data. 
  • Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). 
  • Effect of anti-acetylcholine receptor Fab fragments from goats on functional membrane-bound receptor. 
  • Effectiveness and safety of abciximab after failed thrombolytic therapy. 
  • Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries. 
  • Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials. 
  • Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. 
  • Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. 
  • Efficacy and safety of minimal dose (< or =1,000 units) unfractionated heparin with abciximab in percutaneous coronary intervention. 
  • Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. 
  • Efficacy of abciximab readministration in coronary intervention. 
  • Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. 
  • Embolic protection and platelet inhibition during renal artery stenting. 
  • Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors. 
  • Enhanced delivery of a monoclonal antibody F(ab')2 fragment to subcutaneous human glioma xenografts using local hyperthermia. 
  • Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents. 
  • Ethical considerations in design of a study to evaluate a US Food and Drug Administration-approved indication: antivenom versus placebo for copperhead envenomation. 
  • Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. 
  • Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. 
  • Facilitated PCI in patients with ST-elevation myocardial infarction. 
  • Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. 
  • Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. 
  • Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial). 
  • Final results of the ReoPro readministration registry. 
  • Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine. 
  • Fluorine-18-antimyosin monoclonal antibody fragments: preliminary investigations in a canine myocardial infarct model. 
  • Fluorine-18-labeled monoclonal antibody fragments: a potential approach for combining radioimmunoscintigraphy and positron emission tomography. 
  • Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. 
  • Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. 
  • Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Generalized dead-end elimination algorithms make large-scale protein side-chain structure prediction tractable: implications for protein design and structural genomics. 
  • Generation of a polyclonal Fab phage display library to the protozoan parasite Cryptosporidium parvum. 
  • Generation of a polyclonal fab phage display library to the human breast carcinoma cell line BT-20. 
  • Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. 
  • Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists. 
  • Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. 
  • Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. 
  • High-throughput affinity ranking of antibodies using surface plasmon resonance microarrays. 
  • Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma. 
  • Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. 
  • Immunocytochemical localization of cathepsin D in rabbit skin. 
  • Immunoinhibition of intracellular protein digestion in macrophages. 
  • Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial. 
  • Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. 
  • Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial). 
  • Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. 
  • Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. 
  • Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. 
  • Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited. 
  • Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). 
  • Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction. 
  • Importance of mitral regurgitation inpatients undergoing percutaneous coronary intervention for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. 
  • In reply re: "comparison of F(ab')2 versus Fab antivenom for pit viper envenomation: a prospective, blinded, multicenter, randomized clinical trial". 
  • In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonists c7E3 Fab on the activated clotting time. 
  • In vivo inhibition of renin by antirenin antibodies: potential experimental and clinical applications. 
  • Incidence and predictors of major vascular complications after percutaneous coronary intervention in the glycoprotein IIb/IIIa platelet inhibitor era. 
  • Inflammation, platelets, and glycoprotein IIb/IIIa inhibitors. 
  • Influence of circulating antigen on blood pool activity of a radioiodinated monoclonal antibody. 
  • Initial experience with Crotalidae polyvalent immune Fab (ovine) antivenom in the treatment of copperhead snakebite. 
  • Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. 
  • Integrating statistical pair potentials into protein complex prediction. 
  • Interinstitutional variation in the use of abciximab for percutaneous coronary intervention. 
  • LPS-binding IgG arrests actively motile Salmonella Typhimurium in gastrointestinal mucus. 
  • Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. 
  • Labeling proteins using aryl iodide acylation agents: influence of meta vs para substitution on in vivo stability. 
  • Late outcomes after intervention of vein grafts in diabetics with abciximab use. 
  • Ligation of low-density lipoprotein receptor-related protein with antibodies elevates intracellular calcium and inositol 1,4, 5-trisphosphate in macrophages. 
  • Localization of fluorine-18-labeled Mel-14 monoclonal antibody F(ab')2 fragment in a subcutaneous xenograft model. 
  • Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. 
  • Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial. 
  • Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. 
  • Marked Hypofibrinogenemia and Gastrointestinal Bleeding After Copperhead (Agkistrodon contortrix) Envenomation. 
  • Modulation of the intracellular Ca2+ and inositol trisphosphate concentrations in murine T lymphocytes by the glycosylphosphatidylinositol-anchored protein sgp-60. 
  • Molecular architecture of native HIV-1 gp120 trimers. 
  • Monoclonal antibody F(ab')2 fragment labeled with N-succinimidyl 2,4-dimethoxy-3-halobenzoates: in vivo comparison of iodinated and astatinated fragments. 
  • Monoclonal antibody and F(ab')2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration. 
  • Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. 
  • Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. 
  • Murine monoclonal anti-DNA antibodies penetrate cells, bind to nuclei, and induce glomerular proliferation and proteinuria in vivo. 
  • N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. 
  • Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. 
  • Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial. 
  • Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. 
  • Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. 
  • Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial). 
  • Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial. 
  • PCI at non-PCI centres: immediate or rescue? 
  • PET imaging of osteosarcoma in dogs using a fluorine-18-labeled monoclonal antibody Fab fragment. 
  • Pediatric oncology group utilization of immunologic markers in the designation of acute lymphocytic leukemia subgroups: influence on treatment response. 
  • Perspectives on the future of platelet glycoprotein IIb/IIIa blockade therapy. 
  • Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. 
  • Pharmacokinetics of a radioiodinated monoclonal antibody F(ab')2 fragment in a xenograft model with circulating antigen. 
  • Pharmacokinetics of radiolabeled monoclonal antibody B6.2 in patients with metastatic breast cancer. 
  • Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report. 
  • Platelet function and pharmacologic inhibition. 
  • Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selection. 
  • Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. 
  • Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition? 
  • Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. 
  • Power calculations for large multi-arm placebo-controlled studies of dichotomous outcomes. 
  • Power considerations for trials of two experimental arms versus a standard active control or placebo. 
  • Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody. 
  • Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). 
  • Presumed Copperhead Snakebite and Antivenom Administration in the Third Trimester. 
  • Procedural and clinical outcomes after use of the glycoprotein IIb/IIIa inhibitor abciximab for saphenous vein graft interventions. 
  • Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. 
  • Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial. 
  • Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial. 
  • Radiohalogenation of a monoclonal antibody using an N-succinimidyl 3-(tri-n-butylstannyl)benzoate intermediate. 
  • Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14. 
  • Radioiodinated B6.2 monoclonal antibody: further characterization of a potential radiopharmaceutical for the identification of breast tumors. 
  • Radioiodination of antibodies via N-succinimidyl 2,4-dimethoxy-3-(trialkylstannyl)benzoates. 
  • Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody. 
  • Radiolocalization of human pancreatic tumors in athymic mice by monoclonal antibody DU-PAN 1. 
  • Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. 
  • Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. 
  • Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. 
  • Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. 
  • Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. 
  • Rapid kinetic-based screening of human Fab fragments. 
  • Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. 
  • Readministration of abciximab: interim report of the ReoPro readministration registry. 
  • Recombinant polyclonal antibody libraries. 
  • Recovery from Copperhead Snake Envenomation: Role of Age, Sex, Bite Location, Severity, and Treatment. 
  • Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts. 
  • Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade. 
  • Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials. 
  • Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials. 
  • Reply: severe anaphylactic reaction following crotalidae polyvalent immune fab (ovine) administration for copperhead snakebite. 
  • Retreatment with digoxin immune Fab. 
  • Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial. 
  • Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention. 
  • Roundtable panel discussion: the role of glycoprotein IIb-IIIa receptor inhibitors in acute ischemic coronary syndromes. 
  • ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction. 
  • Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. 
  • Safety of abciximab administration during PCI of patients with previous stroke. 
  • Severe adverse drug reaction following Crotalidae Polyvalent Immune Fab (Ovine) administration for copperhead snakebite. 
  • Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque. 
  • Specificity of cell-cell interactions in sea urchin embryos. Appearance of new cell-surface determinants at gastrulation. 
  • Staging non-small cell carcinoma of the lung using technetium-99m-labeled monoclonal antibodies. 
  • Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. 
  • Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. 
  • Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection. 
  • Structure of active β-arrestin-1 bound to a G-protein-coupled receptor phosphopeptide. 
  • Subcutaneous Crotaline Fab antivenom for the treatment of rattlesnake envenomation in a porcine model. 
  • Superior in-hospital and 30-day outcomes with abciximab versus eptifibatide: a contemporary analysis of 495 consecutive percutaneous coronary interventions. 
  • Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. 
  • Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. 
  • The Binding Mechanisms of Antibodies to DNA from Healthy Subjects and Patients with Systemic Lupus Erythematosus: The Role of Monogamous Bivalency and Fc Dependence. 
  • The EPILOG trial. Abciximab prevents ischemic complications during angioplasty. Evaluation in PTCA to improve Long-Term Outcome with Abciximab GP IIb/IIIa Blockade. 
  • The Efficacy of Antivenin Latrodectus (Black Widow) Equine Immune F(ab')2 Versus Placebo in the Treatment of Latrodectism: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. 
  • The Efficacy of Crotalidae Polyvalent Immune Fab (Ovine) Antivenom Versus Placebo Plus Optional Rescue Therapy on Recovery From Copperhead Snake Envenomation: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. 
  • The benefit of abciximab in percutaneous coronary revascularization is not device-specific. 
  • The complementary use of glycoprotein IIb/IIIa inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention. 
  • The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography. 
  • The localisation of radiolabelled murine monoclonal antibody 81C6 and its Fab fragment in human glioma xenografts in athymic mice. 
  • The potential of monoclonal antibodies to reduce reperfusion injury in myocardial infarction. 
  • The role of glycoprotein IIb/IIIa platelet inhibition in percutaneous coronary intervention in the stent era. 
  • The role of monogamous bivalency and Fc interactions in the binding of anti-DNA antibodies to DNA antigen. 
  • The stoichiometry of trimeric SIV glycoprotein interaction with CD4 differs from that of anti-envelope antibody Fab fragments. 
  • The validity, reliability and minimal clinically important difference of the patient specific functional scale in snake envenomation. 
  • Thromboelastography detects inadequate response to abciximab therapy during stent-assisted cerebral aneurysm coil embolization complicated by stroke. 
  • Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). 
  • Treatment of digitalis intoxication with emphasis on the clinical use of digoxin immune Fab. 
  • Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. 
  • Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. 
  • Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. 
  • Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia. 
  • Two embryonic, tissue-specific molecules identified by a double-label immunofluorescence technique for monoclonal antibodies. 
  • Unfractionated heparin reduces the anti-platelet effects of abciximab but not eptifibatide during PCI. 
  • Unsticking platelets: the role of glycoprotein IIb/IIIa receptor blockade. 
  • Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials. 
  • Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction. 
  • Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. 
  • Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiving glycoprotein IIb/IIIa inhibitors. 
  • Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. 
  • Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. 
  • Visual Function Decline Resulting from Geographic Atrophy: Results from the Chroma and Spectri Phase 3 Trials. 
  • Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons? 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology